• <nav id="c8c2c"></nav>
      • <tfoot id="c8c2c"><noscript id="c8c2c"></noscript></tfoot>
      • <tfoot id="c8c2c"><noscript id="c8c2c"></noscript></tfoot>
      • <nav id="c8c2c"><sup id="c8c2c"></sup></nav>
        <tr id="c8c2c"></tr>
      • a级毛片av无码,久久精品人人爽人人爽,国产r级在线播放,国产在线高清一区二区

          Home>News Center>China
               
         

        SARS vaccine trial runs smoothly to 2nd stage
        By Zhang Feng (China Daily)
        Updated: 2005-07-07 06:04

        A total of 300 volunteers will take part in the second-phase human trials of a SARS (severe acute respiratory syndrome) vaccine, experts said yesterday.

        Scientists in Beijing will carry out trials among volunteers aged 20 to 60 to test the effectiveness of the vaccine in human beings, Zhong Nanshan, president of Chinese Medical Association, told the Guangzhou-based Nanfang Metropolis.

        According to Yin Hongzhang - an official from the State Drug Administration, which is in charge of supervising trials of any new vaccine or drug - the first phase trials involved 36 volunteers at the Sino-Japanese Friendship Hospital in Beijing on May 22, 2004. By early December 2004, antibodies against the disease were found in all volunteers, without obvious side effects.

        The vaccine was produced by Beijing's Sinovac Biotech Co Ltd in 2004 after SARS emerged in 2003 and again in 2004, leaving at least 350 dead, mostly in China.

        Zhong did not release the exact date of the second phase or which hospitals will undertake the trials.

        The 300 volunteers will undergo various medical examinations to record the persistence of antibodies over a nine-month period after the vaccine is administered, Zhong said.

        The first-phase test was designed to show the vaccine could build antibodies in the volunteers without side effects, but not to see how long antibodies remain present in people's bodies, Zhong added.

        Experts say only after a vaccine has passed three phases of human trials will it be licensed for use on the public.

        Up to now, no volunteers who took part in the first-phase trials have reported any side effects, Zhong said.

        "I am fine and have been healthy since I got the vaccine on May 22, 2004," Lan Wanli, a university student based in Beijing, said yesterday. He was the first person in the world to receive the vaccine.

        Lan said he has had a medical examination to test for antibodies but the result is not yet available.

        The second round of tests will involve further experimental verification in other aspects, such as dosage and the schedule for injecting the vaccine to gain a better understanding of how it can be used most effectively, experts said.



        Special police detachment established in Xi'an
        Panda cubs doing well in Wolong
        Suspect arrested in Taiwan
          Today's Top News     Top China News
         

        Taiwan's KMT Party to elect new leader Saturday

         

           
         

        'No trouble brewing,' beer industry insists

         

           
         

        Critics see security threat in Unocal bid

         

           
         

        DPRK: Nuke-free peninsula our goal

         

           
         

        Workplace death toll set to soar in China

         

           
         

        No foreign controlling stakes in steel firms

         

           
          No foreign controlling stakes in steel firms
           
          China-made telescopes race to space
           
          'No trouble brewing,' beer industry insists
           
          HK investors cautious on mainland homes
           
          Law in pipeline to ban money laundering
           
          Overseas students test their Chinese abilities
           
         
          Go to Another Section  
         
         
          Story Tools  
           
          News Talk  
          It is time to prepare for Beijing - 2008  
        Advertisement
                 
        a级毛片av无码
        • <nav id="c8c2c"></nav>
          • <tfoot id="c8c2c"><noscript id="c8c2c"></noscript></tfoot>
          • <tfoot id="c8c2c"><noscript id="c8c2c"></noscript></tfoot>
          • <nav id="c8c2c"><sup id="c8c2c"></sup></nav>
            <tr id="c8c2c"></tr>